Abstract. Cells from dental tissues have a mesenchymal stem cell (MSC) phenotype, are multipotent and can differentiate into osteoblastic cells, as we have previously found. MSCs, due to their tumor-homing ability, are currently being used as cell-based delivery systems for cancer protein therapeutics, such as the TNF-related apoptosis-inducing ligand (TRAIL). In the present study we revealed that dental pulp stem cells (DPSCs) expressed TRAIL to a greater extent when they were differentiated into the osteoblastic lineage. TRAIL affected the viability of undifferentiated DPSCs, while osteoblastic differentiated DPSCs were not sensitive to TRAIL. The expression trend of TRAIL receptors underwent changes during the osteoblastic differentiation of DPSCs exhibiting low DcR2 and high DR5 levels in the undifferentiated DPSCs and an opposite scenario was presented in the differentiated cells. The sensitivity of the undifferentiated DPSCs to the TRAIL-apoptotic effect was also associated with low levels of intracellular anti-apoptotic proteins, such as c-FLIP, XIAP and the activation of caspase-8 and -3. DPSC-differentiated osteoblasts expressing high TRAIL levels were capable to affect the cell viability of the human myeloma cell line H929, thus representing an effective anticancer therapeutic method.
Introduction
Mesenchymal stem cells (MSCs) are multipotent stem cells that have attracted a great interest for their noteworthy multilineage differentiation potential (1, 2) and hypoimmunogenic features (3, 4) . All these properties of MSCs have led to their application in regenerative medicine (5, 6) . Furthermore, due to their tumor-homing ability (7) , MSCs are currently used as cell-based delivery systems of therapeutic proteins for cancer treatment (8, 9) . In particular, through the tumor-homing ability of MSCs, the localized production of a specific therapeutic protein is more helpful than the systemic use of a recombinant protein considering both the effective in situ concentration of the molecule and the reduction of unwanted systemic actions. To this end, pro-apoptotic molecules have been linked to MSCs to counteract tumor growth and a particular interest is evident toward TRAIL (10-13), a cytotoxic protein inducing apoptosis mostly in tumor cells, upon binding to the death domain-containing receptor 4 (DR4) and 5 (DR5). The activity of TRAIL can be modulated following binding with two membrane-bound decoy receptors, namely DcR1 and DcR2, which lacking functional death domains, confer TRAIL resistance to expressing cells (14) .
However, clinical studies based on the use of a recombinant soluble form of TRAIL, consisting of a non-covalently assembled homotrimer, as a whole, did not demonstrate therapeutic efficacy (15, 16) . Over the past decades, many recombinant versions of TRAIL have been generated to enhance its pharmacokinetics and/or antitumor activity (17) . To date, it is evident that at least a hexavalent organization of TRAIL molecules bypass the pharmacokinetic problems, however not the trimeric form (18) . In contrast, in order to manage the insufficient pharmacokinetic properties, several studies have examined the practice of in situ production of a standard soluble TRAIL molecule by different adult stem cells (19) (20) (21) . Furthermore, two studies have reported the antitumor activity of human genetically modified MSCs expressing antibodies in a diabody format (22, 23) . Recently, a MSC line, stably producing TRAIL which is activated in a xenotransplantation tumor model, has been generated (13) . Although the main known source of MSCs is the bone marrow, a wide variety of MSCs have been recognized in dental tissues such as pulp, periodontal ligament and apical papilla, exhibiting several multilineage potencies including osteogenic, adipogenic and neurogenic (24) (25) (26) (27) (28) (29) (30) , besides the expected odontogenic (31) . In our previous studies, we demonstrated the stem cell properties of dental tissues such as pulp, follicle and bud, as well as their ability to differentiate into osteoblasts (32) (33) (34) (35) (36) (37) (38) . According to our findings, differentiated dental pulp stem cells (DPSCs) express high levels of TRAIL. Therefore, we hypothesized that DPSCs could provide, through the production of TRAIL, an effective anticancer therapeutic method. Based on these parameters and considering the pro-apoptotic TRAIL effect, we investigated whether DPSCs differentiated into osteoblasts, expressing high TRAIL levels were capable to affect tumor cell viability.
Materials and methods
Cell cultures. Third molar teeth were obtained from 20 healthy young donors, who gave their written informed consent. The study was approved by the Institutional Review Board of the Department of Dental Science and Surgery-Unit of Periodontology, University of Bari. The dental pulps were dissected, gently washed with phosphate-buffered saline (PBS), reduced to small pieces and digested enzymatically with 3 mg/ml type I collagenase and 4 mg/ml dispase (Gibco; Thermo Fischer Scientific, Uxbridge, UK) in agitation for 1 h at 37˚C. To obtain single cell suspensions, the digested solutions were filtered through a 70-µm BD Falcon strainer (Falcon; BD Biosciences, Sunnyvale, CA, USA). Single cell suspensions, centrifuged at 1,300 rpm, were seeded at 5x10 3 cells/cm 2 in mesenchymal stem cell culture medium supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin-G, 100 µg/ml streptomycin (Gibco; Thermo Fischer Scientific) at 37˚C, in 5% CO 2 , replacing the medium every three days until cells reached confluence. The cells were then trypsinized and seeded into appropriate common culture dishes for characterization and experiments, that provide an efficacious substrate for DPSC adhesion, proliferation and differentiation (39) . For the induction of osteogenic differentiation, the cells were seeded at a density of 3x10 3 cells/cm 2 in α-MEM supplemented with 2% FBS, 10 -8 M dexamethasone and 50 µg/ml ascorbic acid (35) . For some experiments, osteogenic differentiated DPSCs were co-cultured with 1x10 3 /cm 2 H929 cells (from the ATCC, Rockville, MD, USA) with or without anti-TRAIL neutralizing monoclonal antibody (mouse; cat. no. MAB375; 500 ng/ml; R&D Systems, Minneapolis, MN, USA).
Cell viability assay. Cell viability was evaluated by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. DPSCs were cultured in 96-well tissue-culture plates and some of them were selected for the time-point 0 (t 0 ), while the others were differentiated with 50 µg/ml ascorbic acid and dexamethasone (10 -8 M) for 20 days (t 20 ). Both t 0 and t 20 cultures were treated with rh-TRAIL (10-500 ng/ml, TRAIL/TNFSF10; R&D Systems) for 48 h. The cell viability was assessed by adding 0.5 mg/ml MTT to the culture medium followed by a 4-h incubation at 37˚C in a humidified 5% CO 2 atmosphere. To stop the reaction, 150 µl of 0.04 N HCl in absolute isopropanol, was added and the optical density (OD) was read at 570 nm through an automatic plate reader (550 Microplate Reader; Bio-Rad Laboratories Inc., Hercules, CA, USA). The obtained values were normalized to cells in control conditions. RNA isolation and real-time PCR analysis. DPSCs at t 0 and at t 20 were subjected to mRNA extraction using spin columns (RNeasy; Qiagen, Hilden, Germany) according to the manufacturer's instructions. The mRNA (1 µg) was reverse transcribed using SuperScript First-Strand Synthesis System kit (Invitrogen Life Technologies, Carlsbad, CA, USA). The resulting cDNA was subjected to PCR amplification with the iTaq SYBR Green Supermix with ROX kit (Bio-Rad Laboratories), using the Chromo 4 real-time PCR detection system (Bio-Rad Laboratories). The following pairs of oligonucleotides were used for the PCR amplification: TRAIL sense, 5'-AGC AAC ACA TTG TCT CC-3' and antisense, 5'-CCA GTT CAC CAT TCC TCA AG-3'; GAPDH sense 5'-TCA TCC CTG CCT CTA CTG-3' and antisense 5'-TGC TTC ACC ACC TTC TTG-3'. The fold change values were calculated using the Pfaffl method (40) . Statistical analysis. Statistical analysis was performed using Student's t-test with the SPSS 22 (SPSS X/PC) software (SPSS, Inc., Chicago, IL, USA). A value of P<0.05 was considered to indicate statistically significant differences.
Results

Expression of TRAIL increases in DPSCs differentiated towards osteoblasts.
We previously demonstrated that DPSCs cultured in osteogenic medium displayed an osteoblastic phenotype (32, 33) . It is also known from the literature that MSCs produced TRAIL. These findings prompted us to evaluate the expression of TRAIL in undifferentiated DPSCs (t 0 ) and in cultures differentiated for 20 days in osteogenic conditions (t 20 ). We found that undifferentiated DPSCs already expressed TRAIL, however, in the cells cultured for 20 days in osteogenic medium, TRAIL mRNA levels reached a 25-fold increase (Fig. 1A) . These results were also supported by western blotting indicating a 15-fold increase of TRAIL in differentiated DPSCs in respect to undifferentiated cells (Fig. 1B) .
Sensitivity of DPSCs to TRAIL-mediated apoptosis. DPSC sensitivity to TRAIL-apoptotic effect was investigated by analyzing cell viability through an MTT assay in undifferentiated (t 0 ) and differentiated (t 20 ) DPSCs in the presence of TRAIL. Undifferentiated and differentiated DPSCs were first characterized for their osteoblastic parameters (alkaline phosphatase, osteopontin and osteocalcin) exhibiting a weak expression at t 0 and a significant increase at t 20 (data not shown). The cells in both conditions were treated with increasing concentrations of rh-TRAIL (ranging from 10 to 500 ng/ml) for 48 h and their viability was determined in both TRAIL-treated and untreated cells as a control. As observed in Fig. 2A , the viability of t 0 -DPSCs was reduced by TRAIL in a dose-dependent manner. In detail, when undifferentiated cells were treated with 10 ng/ml rh-TRAIL for 48 h their viability was significantly reduced compared to untreated cultures. Treatment with TRAIL at 25 ng/m further decreased the viability of t 0 -DPSCs, while the maximum decrease was observed at 50 ng/ml TRAIL and no additional reduction was observed in the presence of higher concentrations of the cytokine. Unexpectedly, we observed that TRAIL did not induce any effect on cell viability on differentiated DPSCs even at a dose of 50 ng/ml TRAIL (Fig. 2B) , thus demonstrating that DPSCs T 20 , were resistant to TRAIL-induced apoptosis.
Expression of TRAIL receptors during DPSC differentiation.
On the base of the aforementioned results, we explored the possibility that the progression of the osteoblastic differentiation could affect the expression of death and decoy TRAIL receptors in DPSCs. Using western blotting we found that DPSCs constitutively expressed all TRAIL receptors both in undifferentiated conditions and during their differentiation. In particular, the expression of DR5, was high in undifferentiated cells and progressively decreased during the differentiation process, reaching the lowest level in t 20 -DPSCs (Fig. 3) . Additionally, the expression of the decoy receptor DcR2 was low in t 0 -DPSCs and increased ~20% following 20 days of osteoblasic differentiation. The expression of DR4 and DcR1 was not modified (data not shown). Consequently, the ratio between decoy-and death-TRAIL receptors shifted in favor of the death-TRAIL receptors in the undifferentiated DPSCs thus, increasing their sensitivity to TRAIL apoptotic effect. By contrast, the ratio shifted in favor of the decoy receptors during the DPSC osteogenic differentiation. Collectively, these results indicated the absence of the TRAIL effect on the viability of osteogenic differentiated DPSCs (Fig. 2) .
TRAIL activates caspase-8 and -3 in undifferentiated DPSCs
. Based on the above described findings we evaluated the activation of caspase-8 and -3 in TRAIL-treated undifferentiated and differentiated DPSCs. It is known that caspase-8 is the early caspase activated during TRAIL-induced apoptosis in different cell types (41, 42) . Using western blot analysis, we demonstrated the activation of caspase-8 in undifferentiated DPSCs treated with 100 ng/ml TRAIL from 1 up to 8 h. In particular, caspase activation was evident after 6 h of TRAIL treatment (Fig. 4A) . It is also well-known that activated caspase-8 cleaves caspase-3. Thus, we explored whether TRAIL treatment induced the cleavage of caspase-3. As depicted in Fig. 4B , the p17 cleaved form of caspase-3 was found in undifferentiated DPSCs following 6 and 8 h of TRAIL-treatment exposure. According to the MTT assay, we observed that TRAIL failed to induce caspase-8 and -3 activation in differentiated DPSCs (Fig. 4C and D) .
Expression of cFLIP and XIAP during DPSC differentiation.
The reported diverse TRAIL sensitivity of the undifferentiated and differentiated DPSCs prompted us to evaluate the different levels of the intracellular anti-apoptotic molecules cFLIP and XIAP during the DPSC differentiation. Using western blotting we observed that the expression of cFLIP and XIAP increased during the osteoblastic differentiation of DPSCs and the lowest levels of XIAP and cFLIP were demonstrated in undifferentiated DPSCs (Fig. 5) . Thus, our findings indicated that differentiated DPSCs were further preserved from TRAIL pro-apoptotic effect through the increase of the intracellular inhibitors of caspases cFLIP and XIAP (43, 44) .
Differentiated DPSCs affect the viability of the H929 cells through TRAIL.
The above-reported high expression of TRAIL in differentiated DPSCs led us to hypothesize that these cells could be a vehicle of the pro-apoptotic agent for cancer cells and we tested this hypothesis on the human myeloma cell line H929. Firstly, we verified the sensitivity of H929 cells to the TRAIL-apoptotic effect, stimulating the human myeloma cell line with 100 ng/ml TRAIL and assessing the cell viability with an MTT assay. The results indicated a significant decrease of H929 cell viability following treatment, demonstrating that the cells were sensitive to the TRAIL-apoptotic effect (Fig. 6A) . Subsequently, in order to demonstrate that osteoblastic differentiated DPSCs producing TRAIL can induce apoptosis of tumor cells, we co-cultured osteoblastic differentiated DPSCs with H929, with or without a neutralizing anti-TRAIL antibody. Our results indicated that anti-TRAIL antibody treatment exhibited a significant increase of cell viability in the co-culture, which should be related to the neutralization of TRAIL produced by differentiated DPSCs (Fig. 6B) . Anti-TRAIL antibody did not affect cell viability of H929 cells and differentiated DPSCs cultured alone ( Fig. 6C and D) . Notably, cell-cell contact was fundamental for this interaction; in fact the media from osteoblastic differentiated DPSCs did not affect the viability of H929 cells (data not shown). 
Discussion
In the present study, we demonstrated that the expression of TRAIL increased during the osteoblastic differentiation of DPSCs and in parallel, that differentiated DPSCs lost their sensitivity to TRAIL-induced apoptosis. These two properties of DPSCs led us to use these cells as a TRAIL-vehicle to induce an apoptotic effect on H929 myeloma cell line in vitro.
Since its discovery (45, 46) , TRAIL has been broadly considered a potential therapeutic agent, due to its uniqueness of inducing apoptosis in cancer cells while not affecting normal cells (47, 48) . However, sensitivity to its pro-apoptotic effect has also emerged in normal cells, such as bone cells (49) (50) (51) (52) (53) (54) . TRAIL-based therapies performed in numerous clinical trials generated poor results for different reasons, including the defective delivery of the protein to cancer cells. These findings led to the use of DPSCs as a delivery system for cancer cells. We previously characterized DPSCs as an alternative source of MSCs (32,33,35 ) and demonstrated their ability to differentiate into osteoblastic cells. Notably, we observed that differentiated DPSCs expressed higher TRAIL levels and presented a different responsiveness to TRAIL pro-apoptotic effect with respect to undifferentiated DPSCs.
In detail, we found that only undifferentiated DPSCs were sensitive to TRAIL-induced apoptosis in a time-and dose-dependent manner, while DPSCs cultured in osteogenic conditions were resistant. We demonstrated that the diverse responses of undifferentiated and differentiated DPSCs to TRAIL were related to the different expression of TRAIL-receptors DR5 and DCR2 during osteoblastic differentiation. DR5 is a death domain-containing receptor, required for the induction of cell death (55) (56) (57) (58) , while DCR2 is a decoy factor able to counteract the pro-apoptotic action of TRAIL (59, 60) . Our results indicated that undifferentiated DPSCs expressed higher levels of DR5 and lower levels of DcR2 compared to differentiated DPSCs. Thus, in undifferentiated DPSCs the ratio of TRAIL-receptors moved towards the death receptors, leading these cells to be more sensitive to the pro-apoptotic action of TRAIL. Conversely, in differentiated DPSCs the receptor ratio shifted to the decoy receptors, resulting in defense from TRAIL-mediated apoptosis. We demonstrated that cell viability in DPSCs at t 0 was negatively affected by TRAIL treatment, while DPSCs at t 20 were protected from death. However, we hypothesized that cell-resistance or -sensitivity to TRAIL-mediated apoptosis was not only determined by the balance between the expression of its death and decoy receptors, but could be partially related to the levels of certain intracellular anti-apoptotic molecules, such as c-FLIP and XIAP (61) (62) (63) (64) . Supporting the observation of different TRAIL sensitivity between t 0 -and t 20 -DPSCs, we found low levels of the anti-apoptotic factors c-FLIP and XIAP in t 0 -DPSCs, that increased during osteogenic differentiation.
Furthermore, according to the shifted ratio of receptors towards death receptors and low levels of cFLIP and XIAP in undifferentiated DPSCs, we demonstrated, in these cells, after the TRAIL administration, the immediate activation of caspase-8 that in turn resulted in the executioner caspase-3 cleavage starting at 6 h of incubation. These events represented the crucial intracellular steps in the initiation of the apoptotic pathway activated by TRAIL in other cells (65) (66) (67) . Notably, the stimulation of TRAIL failed to activate this pathway in t 20 -DPSCs, since caspase-8 and -3 were almost unexpressed. The latter finding was in agreement with the resistance to TRAIL-mediated cell death exhibited by these cells in osteogenic conditions and with the expression of receptors and anti-apoptotic molecules. The obtained results led us to hypothesize on the possible role of differentiated DPSCs as a vehicle of TRAIL to cancer cells and prompted us to test this hypothesis on cancer cells. We used the human myeloma cell line H929 to test our hypothesis due to its non-adherent behavior in culture. Previous studies have tested the use of MSCs as a vehicle of TRAIL demonstrating the ability to induce either in vitro apoptosis in several cancer cell lines (11) , or in vivo remission of colon tumor and sarcomas established in nude mice (10, 12) . Furthermore, the localized action of TRAIL delivered by MSCs appeared to bypass the resistance of cancer cells, such as breast and colorectal, to soluble TRAIL (68, 69) . More recently, a stable MSC line expressing a highly bioactive form of TRAIL was generated and demonstrated a significant tumor regression in an in vivo Colo205 mouse xenograft tumor model (13) . The advantage of our model is that DPSCs differentiated in osteogenic conditions, expressed high levels of endogenous TRAIL, thus this system did not require any transfection technology and the cells were resistant to TRAIL-mediated apoptosis. Our results indicated that the cell viability of human myeloma H929 cells was affected by the TRAIL-apoptotic effect (Fig. 6A) . Notably when the H929 cells were co-cultured with DPSCs and treated with anti-TRAIL neutralizing antibody, they recovered high levels of cell viability, with a complete rescue of the apoptotic effect (Fig. 6A ). In conclusion, our results revealed that differentiated DPSCs expressed high levels of TRAIL and were not sensitive to its pro-apoptotic effect, thus they may be an optimal carrier of this antitumor agent in cancer cells. Furthermore, the results demonstrated that this effect completely depended on TRAIL. When TRAIL, produced by DPSCs co-cultured with myeloma cells, was neutralized using blocking antibodies, an increase of H929 cell viability was obtained.
Notably, a recent well-designed study indicated that osteoblasts could counteract leukemia progression in mice, while osteoblast impairment promoted the disease. The authors concluded that osteoblasts could be a therapeutic target in akute leukemia, although the basic mechanism of this interesting finding has not yet been described (70) . This study is aligned with our results and it is intriguing to hypothesize that TRAIL expressed by osteoblasts mediates this effect. Collectively, these emerging results suggested that osteoblasts and osteogenic differentiated MSCs could have a potential therapeutic role in hindering tumor progression.
